title: Matrix deactivation: A general approach to improve stability of unstable and reactive pharmaceutical genotoxic impurities for trace analysis.
abstract: Trace analysis of unstable and reactive pharmaceutical genotoxic impurities (GTIs) is a challenging task in pharmaceutical analysis. Many method issues such as insufficient sensitivity, poor precision, and unusual (too high/low) spiking recovery are often directly related to analytes' instability. We report herein a matrix deactivation approach that chemically stabilizes these analytes for analytical method development. In contrast to the conventional chemical derivatization approach where the analytes are transformed into stable detectable species, the matrix deactivation approach chemically deactivates the hypothetical reactive species in the sample matrix. The matrix deactivation approach was developed on the premise that the instability of certain analytes at trace level is caused by reactions between the analytes and low level reactive species in the sample matrix. Thus, quenching the reactivity of the reactive species would be a key to stabilizing the unstable and reactive analytes. For example, electrophilic alkylators could be destabilized by nucleophiles or bases through either nucleophilic substitution or elimination reactions. One way to mask those reactive species is via protonation by adding acids to the diluent. Alternatively, one can use nucleophile scavengers to deplete reactive unknown species in the sample matrix completely, in analogy to the use of antioxidants and metal chelators to prevent oxidation in the analysis of compounds liable to oxidation. This paper reports the application of the matrix deactivation to the analyses of unstable and reactive pharmaceutical genotoxic impurities. Some of the methods have been used to support development of manufacturing processes for drug substances and a recent regulatory filing.
authors.affiliation: Analytical Sciences, GlaxoSmithKline Pharmaceutical R&D, 709 Swedeland Road, King of Prussia, PA 19406, USA. mingjiang.2.sun@gsk.com
authors.forename: Mingjiang
authors.initials: M
authors.lastname: Sun
authors.forename: Lin
authors.initials: L
authors.lastname: Bai
authors.forename: Gerald J
authors.initials: GJ
authors.lastname: Terfloth
authors.forename: David Q
authors.initials: DQ
authors.lastname: Liu
authors.forename: Alireza S
authors.initials: AS
authors.lastname: Kord
mesh_terms: D000477:Alkylating Agents / Q000032:analysis*; D002853:Chromatography, Liquid; D004340:Drug Contamination; D004355:Drug Stability; D016166:Free Radical Scavengers / Q000737:chemistry; D008401:Gas Chromatography-Mass Spectrometry; D006863:Hydrogen-Ion Concentration; D009153:Mutagens / Q000032:analysis*; D021241:Spectrometry, Mass, Electrospray Ionization; D013678:Technology, Pharmaceutical / Q000379:methods*
chemical_list: D000477:Alkylating Agents; D016166:Free Radical Scavengers; D009153:Mutagens